Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
31 hedge funds and large institutions have $10.5M invested in Vyant Bio, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
11% more funds holding
Funds holding: 28 → 31 (+3)
39% less capital invested
Capital invested by funds: $17.3M → $10.5M (-$6.76M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $28K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$380K |
| 2 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$334K |
| 3 |
QGM
Quality Growth Management
Rancho Santa Fe,
California
|
+$157K |
| 4 |
Millennium Management
New York
|
+$94.2K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$91.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Castleark Management
Chicago,
Illinois
|
-$2.81M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.52M |
| 3 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$1.08M |
| 4 |
WC
Woodstock Corp
Boston,
Massachusetts
|
-$197K |
| 5 |
BMO
Beck Mack & Oliver
New York
|
-$163K |
VYNT Hedge Fund Activity: Q4 2014 in Review
31 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2014, worth a combined $10.5M — down 39% from $17.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new VYNT positions and 8 closed out — a net gain of 4 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Royce & Associates, opening a new position worth an estimated $380K. The largest seller was Castleark Management, exiting entirely with an estimated $2.81M sold.
- 31 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2014, up from 28 in Q3 2014.
- Funds reported $10.5M of Vyant Bio, Inc. Common Stock stock for Q4 2014, down 39% quarter-over-quarter.
- 12 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2014 and 8 closed out, a net change of +4 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2014 was Royce & Associates, an estimated $380K added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2014 was Castleark Management, an estimated $2.81M sold.
Based on aggregated 13F filings for Q4 2014.